Canagliflozin CV Benefits Appear to Be Dose-Dependent
'The benefit of canagliflozin on hard clinical endpoints may be dose-dependent, with the 300 mg dose showing a higher efficacy and a similar safety profile,' said first author Elias Elenjickal, MD, of the Research Institute of the McGill University Heath Centre, in Montreal, Quebec, in presenting the findings at the 62nd European Renal Association Congress 2025.
Cardiovascular and renal benefits of SGLT2 inhibitor drugs are well established, and while dose-dependent effects have been reported in some pharmacokinetic studies, none — with the exception of the EMPA-REG OUTCOME trial (which was of empagliflozin) — have formally evaluated the impact of different doses on hard clinical endpoints, Elenjickal noted.
To investigate whether dose indeed plays a role in those cardiovascular and renal endpoints with canagliflozin, Elenjickal and colleagues conducted a post-hoc analysis of the double-blind Canagliflozin Cardiovascular Assessment Study (CANVAS) study, which was part of the pivotal CANVAS Program.
The CANVAS Program included the CANVAS and CANVAS-Renal studies. The results of the two trials were published together as part of the CANVAS program, not independently.
The CANVAS study included 4330 patients with type 2 diabetes and a high cardiovascular risk, including known cardiovascular disease (CVD) or more than 2 risk factors for CVD.
Those patients were randomized 1:1:1 to treatment with canagliflozin 100 mg, canagliflozin 300 mg, or placebo.
Patients in the study had a median age of 61 years, 66% were male, and baseline characteristics between the groups were similar.
With a mean follow-up of 74 months, those in the canagliflozin 300 mg group showed significantly greater reductions in the composite cardiovascular endpoint, including non-fatal myocardial infarction, stroke, or cardiovascular death, compared with placebo (hazard ratio [HR], 0.82; P = .04) after adjustment for factors including age, sex, and history of CVD.
However, these differences were not observed between canagliflozin 100 mg and placebo for the composite endpoint (HR, 0.95; P = .55).
There were no significant differences between the two canagliflozin doses and the incidence of the composite renal endpoint that included doubling of serum creatinine, end-stage kidney disease, or renal death, compared with placebo (HR, 0.48 for canagliflozin 100 mg; P = .03; HR, 0.41 for canagliflozin 300 mg; P = .01).
Those in the 300 mg dose group were less likely to have progression of albuminuria to a higher stage (A1 to A2, or A2 to A3), compared with placebo (HR, 0.83; P = .006), but the difference was not significant with the 100 mg dose (HR, 0.94; P = .33).
Importantly, all-cause mortality was significantly lower with the 300 mg dose compared with placebo (HR, 0.78; P =.03), while the 100 mg group only showed a trend toward lower mortality (HR, 0.89; P = .29).
There were no significant differences between the two dose groups and placebo in terms of the incidence of acute kidney injury, while the 300 mg group had a trend towards fewer severe hyperkalemia episodes (adjusted HR, 0.61; P = .27).
There were no differences observed in safety outcomes between the two dose groups or placebo.
A Gender Difference?
Of note, a further subgroup analysis showed an effect of gender on hospitalization rates for heart failure events: with males in the 300 mg group having a significantly decreased risk of heart failure hospitalization vs placebo (HR,.62), while females in the 300 mg group had an increased risk (HR, 1.72; P for interaction .03).
In the 100 mg group, males also had a lower risk for heart failure hospitalization vs females (HR, 0.65 vs HR, 1.05; P for interaction .37).
As a caveat, Elenjickal noted that males did have a higher burden of CVD at baseline (65% vs 46%).
'Overall, we found that canagliflozin 300 mg significantly reduced major adverse cardiac events, and reduction in all-cause mortality was observed only with a 300 mg dose: not with a 100 mg dose,' Elenjickal said.
'There is evidence of a dose-dependent effect with canagliflozin, which is unique among other SGLT2 inhibitors for hard clinical endpoints,' Elenjickal said.
The CANVAS study was funded by Janssen Research and Development; ClinicalTrials.gov number NCT01032629 .
Elenjickal reported an educational grant from Pfizer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds
Girls and boys who were exclusively breastfed during their first four to six months showed a reduced risk of early puberty, according to a large new study from South Korea that Canadian doctors say could apply here. The study, published in Monday's issue of JAMA Network Open, looked back at the diets and development of more than 300,000 children from 2007 to 2020, based on data from checkups at four to six months of age and before six years. Worldwide, puberty has increasingly begun earlier in kids. Called "central precocious puberty," it's linked to an increased risk of health problems in adulthood, like heart disease, cancer and diabetes, as well as mental health issues like depression and anxiety. The researchers believe that kids who are exclusively breastfed are less likely to develop childhood obesity, a major predisposing factor of early puberty. However, experts note that many mothers face challenges in breastfeeding, which they say should be addressed on a structural level. "The take-home message should be, for parents or to-be parents, that breastfeeding has multiple beneficial health effects for their children," said Dr. Sonia Anand, associate vice-president of global health at McMaster University, who was not involved in the study. "And the second message is it is not always easy to do." Long-term benefits of breastfeeding About 46 per cent of the babies in the South Korean study were exclusively breastfed, more than a third had formula and nearly 20 per cent had both. "The idea is that breastfed kids are less likely to have extra weight and that's the mechanism whereby they're more protected from developing early puberty," said Dr. Kaberi Dasgupta, a professor of medicine and physician scientist at the McGill University Health Centre, who also was not involved in the study. Boys who were fed just formula had a 16 per cent increased risk of early puberty compared with their peers who were only fed breast milk, the researchers found. For exclusively formula-fed girls, the association jumped to 60 per cent. For mixed-fed boys, it was 14 per cent higher, compared with 45 per cent for girls. The researchers noted some caveats to their study. The participants self-reported how long they breastfed their children, for example. It also couldn't include genetic factors like maternal age of puberty. The early part of life is a key time, as that's when a lot of disease risk is set, wrote doctors Lin Yang and Shengxu Li. Though they weren't involved in the study, they wrote an accompanying journal commentary. "Disease starts early, so should its prevention," they said. Dasgupta says there's no reason to think the findings would be different in Canada. Preventing early puberty can also help kids in other ways, she adds. "The earlier your puberty, the shorter you may become," she said. "There's also the stigma around having early signs of being an adult when you're still a kid. Other kids may tease you." Supporting mothers instead of shaming Yang and the researchers say that instead of putting pressure on new moms, a society-wide approach is important. That includes stronger parental leave policies, workplace accommodations like a private space to breastfeed and lactation support services. "I think policy support, raised awareness, as well as creating the environment for women to be able to [breastfeed] is very important," Yang told CBC News. Sleep patterns, physical activity levels and screen time could also be increasing childhood obesity and early puberty rates, Yang and Li wrote in their commentary, as well as environmental pollutants like endocrine disruptors, though she acknowledged there isn't good data on that. In Canada, about 91 per cent of parents start out breastfeeding. About 38 per cent of parents breastfed exclusively for at least six months, Statistics Canada reported in 2024. Of those who stopped before six months, reasons included not having enough breast milk, finding breastfeeding difficult and the child weaning themself off of it. "I think the wrong takeaway and the wrong approach is to shame mothers who try to breastfeed but can't continue," Anand said. Breastfeeding is one factor among many that can influence weight gain in kids. Lifestyle choices like limiting fast food and cooking with more vegetables and lean proteins can also help prevent childhood obesity, doctors say. While the South Korean study doesn't prove that formula feeding causes early puberty, the researchers had a robust data set and the associations are plausible, she said. Anand's own research demonstrated early breastfeeding and for at least six months was associated with lower levels of excess body fat in children at age three. She says she'd like to see other large studies show similar findings to the South Korean to nail down cause and effect. Studies looking at how genes are tied to precocious puberty could also help, she said.
Yahoo
7 hours ago
- Yahoo
Doctors are seeing more non-smokers, especially women, with later-stage lung cancer
TORONTO — Katie Hulan's family doctor thought she might have asthma. Her cough, which had started about a month and a half earlier, was getting progressively worse. So he gave her some puffers to try, but they didn't work. "I was just getting to the point where I couldn't speak at work," said the 37-year-old tech marketing manager. "At the end of the day, I would be in pain just from the shaking and coughing." Her doctor ordered an X-ray that showed a mass on her lung. "(My doctor) said to go to emergency, thinking it was a blood clot," Hulan remembers. After about six hours of more tests, they told her she had stage 4 lung cancer. "That was one of the most devastating moments of my life," she said. "My immediate reaction was, 'I know how this story ends.' And so for me, it just felt completely like a death sentence." She had been healthy, active and didn't smoke. "For me to get a cancer diagnosis was a big shock. And then to have a lung cancer diagnosis was very puzzling for me," said Hulan, who was diagnosed in Toronto in late 2020 and has since moved to Victoria where she continues treatment. She's one of a growing number of non-smokers doctors are seeing with lung cancer. Although smoking remains the leading risk factor, the Canadian Cancer Society estimates about a quarter of lung cancer cases in the country are non-smokers. In addition, more of those non-smokers are women than men and it's not clear why, said Jessica Moffatt, vice-president of programs and advocacy at the Lung Health Foundation. "One of the theories is that potentially estrogen is doing something to perpetuate tumour growth, but it's all theories at this point," she said. What scientists do know is that environmental factors contribute to lung cancer risk, especially radon gas. According to Health Canada, long-term exposure to radon — an invisible, radioactive gas from the breakdown of uranium in soil and rocks — is the number one cause of lung cancer among non-smokers. The agency says radon is present to some degree in every home and urges everyone to get a radon test kit to check their levels. Other risk factors include exposure to second-hand smoke, asbestos and the fine particulate matter in air pollution, Moffatt said. As wildfires rage across the country, the effects of that smoke is "a huge concern for us" and is an area being studied to determine lung cancer risk, she said. Dr. Rosalyn Juergens, a medical oncologist at McMaster University and Hamilton Health Sciences Centre, said studies have shown that people living in areas with high air pollution rates have a higher risk of developing lung cancer. Over about 20 years in practice, she has "absolutely" seen a rise in non-smoking lung cancer patients. "It was uncommon for me, not never, but uncommon for me, to see a never-smoker when I first started in practice. And we are definitely seeing more and more," said Juergens, who is also the president of Lung Cancer Canada. It's not clear whether there are more non-smokers getting lung cancer or if they just make up a greater proportion of the patients as fewer people smoke than ever before, she said. Many of her non-smoking patients are women, but people simply aren't aware of lung cancer as a women's health issue, she said. When non-smokers reach her office, their cancer is often in advanced stages. "More women will die of lung cancer than will die of breast cancer, ovarian cancer, and cervical cancer combined," Juergens said. "One in five of them will be people who have never touched a cigarette a day in their lives." Although organized lung cancer screening programs have been running in British Columbia, Ontario and Nova Scotia since 2022, they only target smokers, so non-smokers don't get the benefit of that early detection. In addition, lung cancer is often not top-of-mind for primary-care providers when non-smoking patients come in with a cough, Juergens said. "The tricky part about lung cancer is symptoms are generally very subtle, right? Your lungs inside don't have nerve endings. So it's not like you're going to get a pain. You're never going to feel a lump," she said. But the good news for many patients, Juergens said, is that lung cancer treatment has advanced dramatically since the 1990s, when chemotherapy was often the only option. "We do things called next generation sequencing on the vast majority of lung cancers, and that helps us to sort what exact type of lung cancer it is and pick the right treatments," she said. That precision medicine turned Katie Hulan's initial life expectancy of six months into an average of five to six years. A biopsy showed that her cancer had an ALK genetic mutation — one of about a dozen biomarkers that have specific medications to target the cancerous cells, and is only present in about four per cent of cases. "When I got that news, it felt like a 180. I had life. I had hope. You know, my oncologist sat down and said, 'you won the lottery, you have years,'" she said. Almost five years after her diagnosis, Hulan continues to take a pill as her treatment, never had to undergo chemotherapy, feels "wonderful" and is determined to live a long, full life. She now does advocacy work for the Lung Health Foundation to call for equal access to targeted cancer medication across the country and to urge people to seek medical attention if they have a cough that lasts more than two or three weeks. "I think the word on the street is that you have to be a person who has smoked and that's not at all the case," she said. "Anyone with lungs can get lung cancer." This report by The Canadian Press was first published Aug. 18, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Nicole Ireland, The Canadian Press
Yahoo
7 hours ago
- Yahoo
I'm in my 60s — I put this $13 'Botox in a bottle' from a Canadian brand to the test
Shoppers are obsessed with this affordable anti-aging product. But does it live up to the hype? Aging is a natural part of life, but if you're not so into fine lines and wrinkles, you might want to check out The Ordinary's Argireline Solution 10% Serum for Facial Wrinkles. The Canadian company's serum has been dubbed "Botox in a bottle" by shoppers, and the best part? It's super affordable, ringing in at under $15. The brand's website categorizes it as a "non-injective solution for dynamic lines" specifically designed to target signs of aging. The serum almost seems too good to be true, so both my mom — who's in her 60s — and I decided to put it to the test to see if it lives up to the claims. Scroll down for our honest review. The Ordinary Argireline Solution 10% Serum for Facial Wrinkles review: What is it and what are the claims? The Ordinary's Argireline Solution serum is formulated to target skincare concerns such as fine lines and wrinkles, thanks to an Argireline Peptide Complex. As outlined on Sephora, this complex allegedly helps improve the overall appearance of the eye area and forehead, which are two prominent spots on the face that are most prone to creasing or developing folds in the skin. This affordable serum also features a lightweight texture. For best results, it's recommended to apply a few drops to the forehead and around the eye area twice a day. As The Ordinary's website suggests, you can incorporate this product into your routine after cleansing and before applying any anhydrous serums, oils, suspensions, or creams. also recommends avoiding the use of products featuring Direct acids, Direct/Ethylated Vitamin C, and Resveratrol 3% + Ferulic Acid 3% in the same skincare regimen as The Ordinary's Argireline Solution contains Peptides. First impressions As someone in her 60s, my mom is always on the hunt for new products to help target fine lines and wrinkles, so she was excited to give The Ordinary's Argireline Solution a go. This was her skin in the morning before she applied the serum — right after cleansing. She then applied a few drops of the Argireline Solution to her forehead and around the eye area, as recommended. Although she didn't notice a drastic physical change, my mom did note that the product felt tightening upon application, firming her skin after use. Best of beauty: I'm a dermatologist — 3 'universal' skincare staples I always recommend for anti-aging Cheekbone Beauty is Canadian, Indigenous-owned and sustainable — and these celebrities are 'adamant' about using it I'm a celebrity esthetician — this is the 'gold standard' for anti-aging Then, it was my turn. As a 27-year-old, I have always been curious about elevating my skincare routine and have become increasingly interested in finding preventative products that can reduce the look of fine lines as I age. As a result, I was eager to put The Ordinary's Argireline Solution to the test to see if it would actually work on both young and mature skin. Similarly to my mom, I applied a few drops of the lightweight serum to my forehead and eye area after cleansing. I, too, immediately noticed a tightening sensation after application but no immediate physical results- except for my skin appearing to look slightly smoother. It's important to note that it is recommended to use this product twice daily, so we will likely see improved results through more consistent use. What shoppers are saying This affordable serum has a 4-star rating on Sephora, based on more than 400 customer reviews. "Love this product," raved one shopper who deemed it "a staple" for them. "I'm on my third bottle," they added. One 72-year-old customer who has "spent thousands on expensive products" said, "I believe I found the holy [grail with] this stuff!" They said that after "a few weeks," their "fine lines have lessened," and their "deeper lines have softened" — even their "neck wrinkles." However, other shoppers claimed to have not seen any "noticeable improvements" after use, alleging that the product does not minimize the appearance of wrinkles as claimed. Is it worth it? It's worth noting that some skincare solutions take a couple of weeks to perform, so we decided to consistently use this product day and night, as recommended, to see if it garners any notable results. Consistency seems to be key when it comes to The Ordinary's Argireline Solution, as verified by other Sephora shoppers who have used and loved the product. Here's what we noticed after diligently using The Ordinary's Argireline Solution day and night for the past two weeks: Although my mom didn't notice a significant physical difference in her appearance, she did note that her skin felt smoother. For the price, she found that The Ordinary's Argireline Solution was definitely worth a try, and she will continue to use the product to monitor how her skin looks over time. After two weeks of consistent use, I, too, didn't notice a huge difference in the way my skin looked. However, I don't have excessive fine lines or wrinkles, so I may consider this to be more of a preventative skincare product in my everyday beauty routine. That said, I did appreciate how smooth my skin felt after use. I agree that this product is worth the hype in terms of the price tag if you're looking for an affordable way to improve skin smoothness and firmness. Even though it truthfully may be too early to claim that this product is "Botox in a bottle," our opinions may change after more consistent use, so we recommend giving it a fair shot (no pun intended) if you're looking to try it out yourself — especially for $13.
